{
  "id": 9570445,
  "title": "Lilly’s latest China drug deal; Immunovant’s setback in lupus",
  "url": "https://urgent.news/2026/09/24/lillys-latest-china-drug-deal-immunovants-setback-in-lupus",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-24T14:14:00.000Z",
  "source": {
    "name": "BioPharma Dive",
    "slug": "biopharma-dive",
    "url": "https://www.biopharmadive.com/news/lilly-innocare-immunovant-vertex-inaxaplin-otsuka-ionis/831044/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Lilly wagered up to $3.35 billion in its fourth China-focused alliance since January 2025. Elsewhere, analysts are now more confident about one of Vertex’s top prospects and an RNA drug succeeded against a rare form of ALS.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}